ALX Oncology Holdings Inc. (ALXO) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.96
↓-70% vs avg
5yr avg: 3.25
30Y Low0.8·High8.0
ROE
↓
-88.9%
↑-84% vs avg
5yr avg: -48.3%
30Y Low-433%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ALXO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ALX Oncology Holdings Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $112M | $87M | $640M | $459M | $866M | $3.4B | — | — |
| Enterprise Value | $111M | $87M | $635M | $420M | $503M | $3.0B | — | — |
| P/E Ratio → | -0.81 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 2905.75 | — | — |
| P/B Ratio | 0.96 | 0.77 | 3.37 | 1.74 | 2.39 | 7.99 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ALXO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 2538.39 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
ALXO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -88.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 9.1% | 9.1% | 9.0% |
| Operating Margin | — | — | — | — | — | -3694.0% | -400.0% | -662.0% |
| Net Profit Margin | — | — | — | — | — | -3869.7% | -401.2% | -664.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -88.9% | -88.9% | -71.0% | -39.4% | -21.1% | -21.3% | -433.4% | -150.0% |
| ROA | -69.1% | -69.1% | -58.6% | -36.0% | -20.5% | -20.5% | -176.2% | -123.0% |
| ROIC | -71.8% | -71.8% | -62.4% | -84.9% | -50537.3% | — | — | -1149.3% |
| ROCE | -84.8% | -84.8% | -70.3% | -39.6% | -21.0% | -20.1% | -256.1% | -147.3% |
ALXO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $18M exceeds total debt of $17M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.09 | 0.04 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.03 | -0.15 | -1.00 | -1.01 | — | -0.90 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -82.40 | -82.40 | -108.80 | -535.45 | -6427.31 | -53.84 | -913.48 | — |
Net cash position: cash ($18M) exceeds total debt ($17M)
ALXO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ALX Oncology Holdings Inc.'s current ratio of 7.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 9.57x to 7.26x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.26 | 7.26 | 5.24 | 9.57 | 24.00 | 70.28 | 1.97 | 5.45 |
| Quick Ratio | 7.26 | 7.26 | 5.24 | 9.57 | 24.00 | 70.28 | 1.97 | 5.45 |
| Cash Ratio | 6.91 | 6.91 | 5.08 | 9.40 | 23.78 | 69.99 | 1.81 | 4.41 |
| Asset Turnover | — | — | — | — | — | 0.00 | 0.45 | 0.19 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 40.79 | 164.58 |
ALXO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ALX Oncology Holdings Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $52M | $43M | $41M | $40M | $40M | $22M | $22M |
Peer Comparison
Compare ALXO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ALXOYou | $112M | -0.8 | — | — | — | — | -88.9% | -71.8% | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 EXEL | $12B | 17.5 | 13.4 | 14.7 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 TGTX | $7B | 15.2 | 55.7 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See ALXO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALXO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALXO vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonALXO — Frequently Asked Questions
Quick answers to the most common questions about buying ALXO stock.
What is ALX Oncology Holdings Inc.'s P/E ratio?
ALX Oncology Holdings Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
What is ALX Oncology Holdings Inc.'s ROE?
ALX Oncology Holdings Inc.'s return on equity (ROE) is -88.9%. The historical average is -117.9%.
Is ALXO stock overvalued?
Based on historical data, ALX Oncology Holdings Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.